Glaukos (GKOS) to Release Quarterly Earnings on Thursday

Glaukos (NYSE:GKOS - Get Free Report) is projected to issue its quarterly earnings data after the market closes on Thursday, February 20th. Analysts expect the company to announce earnings of ($0.38) per share and revenue of $100.72 million for the quarter. Parties that are interested in registering for the company's conference call can do so using this link.

Glaukos Stock Up 4.6 %

Shares of GKOS traded up $6.68 during mid-day trading on Friday, hitting $153.06. 747,257 shares of the company's stock were exchanged, compared to its average volume of 495,754. The firm has a fifty day moving average of $151.66 and a two-hundred day moving average of $138.37. Glaukos has a twelve month low of $83.90 and a twelve month high of $163.71. The stock has a market cap of $8.44 billion, a price-to-earnings ratio of -50.68 and a beta of 1.04. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on GKOS shares. Piper Sandler reaffirmed an "overweight" rating and set a $180.00 price objective (up from $140.00) on shares of Glaukos in a report on Monday, January 27th. Citigroup raised shares of Glaukos from a "neutral" rating to a "buy" rating and upped their price objective for the stock from $132.00 to $162.00 in a report on Wednesday, December 11th. Stephens raised shares of Glaukos to a "strong-buy" rating in a report on Monday, December 2nd. Truist Financial upped their price objective on shares of Glaukos from $152.00 to $185.00 and gave the stock a "buy" rating in a report on Wednesday, December 18th. Finally, Morgan Stanley downgraded shares of Glaukos from an "equal weight" rating to an "underweight" rating and set a $120.00 price objective for the company. in a report on Monday, December 2nd. One analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $151.08.

Insider Buying and Selling at Glaukos

In other news, Director Gilbert H. Kliman sold 2,000 shares of the firm's stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $144.01, for a total transaction of $288,020.00. Following the completion of the transaction, the director now directly owns 32,336 shares of the company's stock, valued at approximately $4,656,707.36. This trade represents a 5.82 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Joseph E. Gilliam sold 3,328 shares of the firm's stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $149.85, for a total transaction of $498,700.80. Following the transaction, the chief operating officer now directly owns 102,169 shares of the company's stock, valued at $15,310,024.65. The trade was a 3.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 15,328 shares of company stock valued at $2,289,521 in the last ninety days. Company insiders own 6.40% of the company's stock.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.